Cooling the Uterus in C-section After Dysfunctional Labor

Blood Loss Clinical Trial

Official title:

Can Cooling the Uterus During Cesarean Delivery Reduce Blood Loss, Reduce Drug Use, and Decrease the Risk for Hysterectomy in Women With Dysfunctional Labor?

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT02910115
• Other study ID #: 015-028
• Status: Enrolling by invitation
• Phase: N/A
• First received: January 14, 2016
• Last updated: June 9, 2017
• Start date: September 2016
• Est. completion date: September 2018

Study information

• Verified date: June 2017
• Source: Baylor Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to demonstrate whether cooling the uterine smooth muscle during cesarean section (following delivery of the fetus) will promote better uterine contraction and involution resulting in lower blood loss, use of fewer uterotonic medications, and fewer hysterectomies following cesarean section for dysfunctional labor.

Description:

Two hundred patients will be drawn from all pregnant women who require a cesarean delivery for dysfunctional labor. Dysfunctional labor will be defined as cervical dilation of 3 or more centimeters, in active labor without cervical change for 2 or more hours. Patients will be randomly assigned to the study group or the control group, and each group will have 100 patients.

Following the delivery of the fetus, patients in the control group will have IV Pitocin administered per the usual protocol and the uterus will be wrapped in lab sponges soaked in room-temperature saline while the uterine incision is closed per the attending obstetrician's usual practice. Additional utero-tonic medications may be given to improve uterine contraction.

In the study group, following the delivery of the fetus, the uterus will be externalized in the usual fashion, except the uterus will be wrapped with lap sponges saturated in sterile, iced normal saline. Additional utero-tonic medications may also be given in the study group to improve uterine contraction.

Immediately after the delivery of the fetus and prior to the delivery of the placenta, the amniotic fluid and blood on the surgical field will be aspirated into the suction canister. This amount of fluid in the suction canister will be noted and subtracted from the amount of fluid in the canister at the conclusion of the surgery.

At the conclusion of the surgery, blood loss will be calculated by measuring the content of blood in the suction canister, and by weighing the surgical sponges. Post surgical vaginal bleeding will be monitored and calculated until the patient is discharged from the labor and delivery unit. Use of utero-tonic medications will be recorded.

At the conclusion of the study, the amount of blood loss and utero-tonic drugs between the control and study groups will be compared. The need for additional surgeries, such as a hysterectomy or D&C, will be compared between the two groups.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 100
• Est. completion date: September 2018
• Est. primary completion date: September 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• pregnant women of any age

• gravidity and gestational duration who present for cesarean section and who have given informed consent to be in the study.

Exclusion criteria:

• Women who refuse to be in the study

• women who are unable to consent due to emergent nature of the cesarean section

• women who are unable to understand the nature of the study due to mental illness, mental retardation, medical condition, or other communication barrier will be excluded.

Related Conditions & MeSH terms

• Blood Loss
• Dysfunctional Labor
• Dystocia
• Hemorrhage
• Uterine Atony
• Uterine Inertia

Intervention

Other:
• Cold laparotomy sponges
Cold laparotomy sponges are lap sponges that are saturated in sterile, iced normal saline

Drug:
• Pitocin
Pitocin is administered intravenously according to the usual protocol.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Baylor Research Institute

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Estimated Blood Loss		up to 24 hours after surgery
Secondary	Change in Hematocrit		up to 24 hours after surgery
Secondary	Need for use of uterotonic medications		during cesarean section